繁体中文
设为首页
加入收藏
当前位置:药品说明书与价格首页 >> 上市新药 >> SPIRIVA RESPIMAT(tiotropium bromide inhalation spray)

SPIRIVA RESPIMAT(tiotropium bromide inhalation spray)

2016-03-18 12:54:42  作者:新特药房  来源:互联网  浏览次数:0  文字大小:【】【】【
简介: 英文药名:SPIRIVA RESPIMAT(tiotropium bromide inhalation spray) 中文药名:噻托嗅按吸入气雾剂 生产厂家:勃林格殷格翰药品介绍Spiriva Respimat第一类新的吸入气雾剂获FDA批准2014年9月26日,美 ...

英文药名:SPIRIVA RESPIMAT(tiotropium bromide inhalation spray)

中文药名:噻托嗅按吸入气雾剂

生产厂家:勃林格殷格翰
药品介绍
Spiriva Respimat第一类新的吸入气雾剂获FDA批准
2014年9月26日,美国FDA批准Spiriva Respimat(tiotropium bromide,噻托嗅按)吸入气雾剂,作为一种长期的、每日一次的维持性药物,用于慢性阻塞性肺病(COPD,包括慢性支气管炎和肺气肿)支气管痉挛的治疗,以及减少COPD急性加重。
Spiriva Respimat将为COPD提供一种重要的治疗选择,尤其是初诊COPD患者。
Spiriva Respimat具有与已上市药物Spiriva HandiHaler相同的活性成分(噻托溴铵粉吸入剂),在美国,Spiriva HandiHaler是处方量排名第一的COPD维持药物,勃林格表示,该药将继续作为COPD患者的一种治疗选择。Spiriva Respimat的开发,旨在不依赖空气快速通过吸入器的方式递送药物,而是通过一种缓慢移动的气雾递送定量的药物。


HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use SPIRIVA RESPIMAT safely and effectively. See full prescribing information for SPIRIVA RESPIMAT.
SPIRIVA® RESPIMAT® (tiotropium bromide) inhalation spray, for oral inhalation
Initial U.S. Approval: 2004
RECENT MAJOR CHANGES

Indications and Usage (1.2) 9/2015
Dosage and Administration (2, 2.1, 2.2, 2.3) 9/2015
INDICATIONS AND USAGE
SPIRIVA RESPIMAT is an anticholinergic indicated for:
The long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), and for reducing COPD exacerbations (1.1)
The long-term, once-daily, maintenance treatment of asthma in patients 12 years of age and older (1.2)
Limitation of Use:
Not indicated for relief of acute bronchospasm (1.1, 1.2, 5.1)
DOSAGE AND ADMINISTRATION
For oral inhalation only
To receive the full dose of medication, SPIRIVA RESPIMAT must be administered as two inhalations once-daily.
Treatment of COPD: 2 inhalations of SPIRIVA RESPIMAT 2.5 mcg once-daily (2)
Treatment of asthma patients 12 years and older: 2 inhalations of SPIRIVA RESPIMAT 1.25 mcg once-daily (2)
DOSAGE FORMS AND STRENGTHS
Inhalation spray: 1.25 mcg or 2.5 mcg tiotropium per actuation with the SPIRIVA RESPIMAT inhaler. Two actuations equal one dose (2.5 mcg or 5 mcg). (3)
CONTRAINDICATIONS
Hypersensitivity to tiotropium, ipratropium, or any component of this product (4)
WARNINGS AND PRECAUTIONS
Not for acute use, i.e., not a rescue medication (5.1)
Immediate hypersensitivity reactions: Discontinue SPIRIVA RESPIMAT at once and consider alternatives if immediate hypersensitivity reactions, including angioedema, bronchospasm, or anaphylaxis, occur. (5.2)
Paradoxical bronchospasm: Discontinue SPIRIVA RESPIMAT and consider other treatments if paradoxical bronchospasm occurs. (5.3)
Worsening of narrow-angle glaucoma may occur. Use with caution in patients with narrow-angle glaucoma and instruct patients to consult a physician immediately if this occurs. (5.4)
Worsening of urinary retention may occur. Use with caution in patients with prostatic hyperplasia or bladder-neck obstruction and instruct patient to consult a physician immediately if this occurs. (5.5)
ADVERSE REACTIONS
The most common adverse reactions in:
COPD: (>3% incidence in the placebo-controlled trials with treatment durations of between 4 and 48 weeks) were pharyngitis, cough, dry mouth, and sinusitis. (6.1).
Asthma: (>2% incidence in the placebo-controlled trials with treatment durations of between 12 and 52 weeks) were pharyngitis, sinusitis, bronchitis, and headache in adults (6.2).
To report SUSPECTED ADVERSE REACTIONS, contact Boehringer Ingelheim Pharmaceuticals, Inc. at (800) 542-6257 or (800) 459-9906 TTY or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
DRUG INTERACTIONS
Anticholinergics: May interact additively with concomitantly used anticholinergic medications. Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (7.2)
USE IN SPECIFIC POPULATIONS
Patients with moderate to severe renal impairment should be monitored closely for potential anticholinergic side effects. (2, 8.6)
See 17 for PATIENT COUNSELING INFORMATION.
Revised: 1/2016
FULL PRESCRIBING INFORMATION: CONTENTS*
1 INDICATIONS AND USAGE
1.1 Maintenance Treatment of Chronic Obstructive Pulmonary Disease
SPIRIVA RESPIMAT (tiotropium bromide) is indicated for the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. SPIRIVA RESPIMAT is indicated to reduce exacerbations in COPD patients.
Important Limitation of Use:
SPIRIVA RESPIMAT is NOT indicated for the relief of acute bronchospasm.
1.2 Maintenance Treatment of Asthma
SPIRIVA RESPIMAT is a bronchodilator indicated for the long-term, once-daily, maintenance treatment of asthma in patients 12 years of age and older.
Important Limitation of Use:
SPIRIVA RESPIMAT is NOT indicated for the relief of acute bronchospasm.
2 DOSAGE AND ADMINISTRATION
To receive the full dose of medication, SPIRIVA RESPIMAT must be administered as two inhalations once-daily. Do not take more than one dose (2 inhalations) in 24 hours.
Prior to first use, the SPIRIVA RESPIMAT cartridge is inserted into the SPIRIVA RESPIMAT inhaler and the unit is primed. When using the unit for the first time, patients are to actuate the inhaler toward the ground until an aerosol cloud is visible and then repeat the process three more times. The unit is then considered primed and ready for use. If not used for more than 3 days, patients are to actuate the inhaler once to prepare the inhaler for use. If not used for more than 21 days, patients are to actuate the inhaler until an aerosol cloud is visible and then repeat the process three more times to prepare the inhaler for use [see Patient Counseling Information (17)].
2.1 Chronic Obstructive Pulmonary Disease
The recommended dosage for patients with COPD is 2 inhalations of SPIRIVA RESPIMAT 2.5 mcg per actuation once-daily; total dose equals 5 mcg of SPIRIVA RESPIMAT.
2.2 Asthma
The recommended dosage for patients with asthma is 2 inhalations of SPIRIVA RESPIMAT 1.25 mcg per actuation once-daily; total dose equals 2.5 mcg of SPIRIVA RESPIMAT. In the treatment of asthma, the maximum benefits in lung function may take up to 4 to 8 weeks of dosing [see Patient Counseling Information (17)].
2.3 Special Populations
No dosage adjustment is required for geriatric, hepatically-impaired, or renally-impaired patients. However, patients with moderate to severe renal impairment given SPIRIVA RESPIMAT should be monitored closely for anticholinergic effects [see Warnings and Precautions (5.6), Use in Specific Populations (8.5, 8.6, 8.7), and Clinical Pharmacology (12.3)]. 
3 DOSAGE FORMS AND STRENGTHS
SPIRIVA RESPIMAT consists of a SPIRIVA RESPIMAT inhaler and an aluminum cylinder (SPIRIVA RESPIMAT cartridge) containing tiotropium bromide (as the monohydrate). The SPIRIVA RESPIMAT cartridge is only intended for use with the SPIRIVA RESPIMAT inhaler.
SPIRIVA RESPIMAT is available in two dosage strengths. Each actuation from the SPIRIVA RESPIMAT inhaler delivers 1.25 mcg or 2.5 mcg of tiotropium (equivalent to 1.562 mcg or 3.124 mcg, respectively, of tiotropium bromide monohydrate) from the mouthpiece. Two actuations equal one dose (2.5 mcg or 5 mcg).
4 CONTRAINDICATIONS
SPIRIVA RESPIMAT is contraindicated in patients with a hypersensitivity to tiotropium, ipratropium, or any component of this product [see Warnings and Precautions (5.2)]. In clinical trials with SPIRIVA RESPIMAT, immediate hypersensitivity reactions, including angioedema (including swelling of the lips, tongue, or throat), itching, or rash have been reported [see Warnings and Precautions (5.2)].
5 WARNINGS AND PRECAUTIONS
5.1 Not for Acute Use
SPIRIVA RESPIMAT is intended as a once-daily maintenance treatment for COPD and asthma and should not be used for the relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of bronchospasm. In the event of an acute attack, a rapid-acting beta2-agonist should be used.
5.2 Immediate Hypersensitivity Reactions
Immediate hypersensitivity reactions, including urticaria, angioedema (including swelling of the lips, tongue or throat), rash, bronchospasm, anaphylaxis, or itching may occur after administration of SPIRIVA RESPIMAT. If such a reaction occurs, therapy with SPIRIVA RESPIMAT should be stopped at once and alternative treatments should be considered. Given the similar structural formula of atropine to tiotropium, patients with a history of hypersensitivity reactions to atropine or its derivatives should be closely monitored for similar hypersensitivity reactions to SPIRIVA RESPIMAT.
5.3 Paradoxical Bronchospasm
Inhaled medicines, including SPIRIVA RESPIMAT, may cause paradoxical bronchospasm. If this occurs, it should be treated immediately with an inhaled short-acting beta2-agonist such as albuterol. Treatment with SPIRIVA RESPIMAT should be stopped and other treatments considered.
5.4 Worsening of Narrow-Angle Glaucoma
SPIRIVA RESPIMAT should be used with caution in patients with narrow-angle glaucoma. Prescribers and patients should be alert for signs and symptoms of acute narrow-angle glaucoma (e.g., eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema). Instruct patients to consult a physician immediately should any of these signs or symptoms develop.
5.5 Worsening of Urinary Retention
SPIRIVA RESPIMAT should be used with caution in patients with urinary retention. Prescribers and patients should be alert for signs and symptoms of urinary retention (e.g., difficulty passing urine, painful urination), especially in patients with prostatic hyperplasia or bladder-neck obstruction. Instruct patients to consult a physician immediately should any of these signs or symptoms develop.
5.6 Renal Impairment
As a predominantly renally excreted drug, patients with moderate to severe renal impairment (creatinine clearance of <60 mL/min) treated with SPIRIVA RESPIMAT should be monitored closely for anticholinergic side effects [see Clinical Pharmacology (12.3)].
6 ADVERSE REACTIONS
The following adverse reactions are described, or described in greater detail, in other sections:
Immediate hypersensitivity reactions [see Warnings and Precautions (5.2)]
Paradoxical bronchospasm [see Warnings and Precautions (5.3)]
Worsening of narrow-angle glaucoma [see Warnings and Precautions (5.4)]
Worsening of urinary retention [see Warnings and Precautions (5.5)]
Because clinical trials are conducted under widely varying conditions, the incidence of adverse reactions observed in the clinical trials of a drug cannot be directly compared to the incidences in the clinical trials of another drug and may not reflect the incidences observed in practice.
Since the same active ingredient (tiotropium bromide) is administered to COPD and asthma patients, prescribers and patients should take into account that the observed adverse reactions could be relevant for both patient populations independent of dosage strength.
6.1 Clinical Trials Experience in Chronic Obstructive Pulmonary Disease
The SPIRIVA RESPIMAT clinical development program included ten placebo controlled clinical trials in COPD. Two trials were four-week cross-over trials and eight were parallel group trials. The parallel group trials included a three week dose-ranging trial, two 12-week trials, three 48-week trials, and two trials of 4-week and 24-week duration conducted for a different program that contained tiotropium bromide 5 mcg treatment arms. The primary safety database consists of pooled data from the 7 randomized, parallel-group, double-blind, placebo-controlled studies of 4-48 weeks in treatment duration. These trials included 6565 adult COPD patients (75% males and 25% females) 40 years of age and older. Of these patients, 3282 patients were treated with SPIRIVA RESPIMAT 5 mcg and 3283 received placebo. The SPIRIVA RESPIMAT 5 mcg group was composed mostly of Caucasians (78%) with a mean age of 65 years and a mean baseline percent predicted post-bronchodilator FEV1 of 46%.
In these 7 clinical trials, 68.3% of patients exposed to SPIRIVA RESPIMAT 5 mcg reported an adverse event compared to 68.7% of patients in the placebo group. There were 68 deaths in the SPIRIVA RESPIMAT 5 mcg treatment group (2.1%) and 52 deaths (1.6%) in patients who received placebo [see Clinical Studies (14) Long-term active controlled mortality trial: Survival]. The percentage of SPIRIVA RESPIMAT patients who discontinued due to an adverse event were 7.3% compared to 10% with placebo patients. The percentage of SPIRIVA RESPIMAT 5 mcg patients who experienced a serious adverse event were 15.0% compared to 15.1% with placebo patients. In both groups, the adverse event most commonly leading to discontinuation was COPD exacerbation (SPIRIVA RESPIMAT 2.0%, placebo 4.0%) which was also the most frequent serious adverse event. The most commonly reported adverse reactions were pharyngitis, cough, dry mouth, and sinusitis (Table 1). Other adverse reactions reported in individual patients and consistent with possible anticholinergic effects included constipation, dysuria, and urinary retention.
Table 1 shows all adverse reactions that occurred with an incidence of >3% in the SPIRIVA RESPIMAT 5 mcg treatment group, and a higher incidence rate on SPIRIVA RESPIMAT 5 mcg than on placebo.
Table 1 Number Percentage) of COPD Patients Exposed to SPIRIVA RESPIMAT 5 mcg with Adverse Reactions >3% (and Higher than Placebo): Pooled Data from 7 Clinical Trials with Treatment Periods Ranging between 4 and 48 Weeks in COPD Patients 

Body System (Reaction)* SPIRIVA RESPIMAT 5 mcg
[n=3282]
Placebo
[n=3283]
     
Gastrointestinal Disorders    
     Dry mouth 134 (4.1) 52 (1.6)
Infections and Infestations    
     Pharyngitis 378 (11.5) 333 (10.1)
Respiratory, Thoracic, and Mediastinal Disorders    
     Cough 190 (5.8) 182 (5.5)
     Sinusitis 103 (3.1) 88 (2.7)
*Adverse reactions include a grouping of similar terms
Other reactions that occurred in the SPIRIVA RESPIMAT 5 mcg group at an incidence of 1% to 3% and at a higher incidence rate on SPIRIVA RESPIMAT 5 mcg than on placebo included: Cardiac disorders: palpitations; Gastrointestinal disorders: constipation; gastroesophageal reflux disease; oropharyngeal candidiasis; Nervous system disorders: dizziness; Respiratory system disorders (Upper): dysphonia; Skin and subcutaneous tissue disorders: pruritus, rash; Renal and urinary disorders: urinary tract infection.
Less Common Adverse Reactions
Among the adverse reactions observed in the clinical trials with an incidence of <1% and at a higher incidence rate on SPIRIVA RESPIMAT 5 mcg than on placebo were: dysphagia, gingivitis, intestinal obstruction including ileus paralytic, joint swelling, dysuria, urinary retention, epistaxis, laryngitis, angioedema, dry skin, skin infection, and skin ulcer.
6.2 Clinical Trials Experience in Asthma
Adult Patients
SPIRIVA RESPIMAT 2.5 mcg has been compared to placebo in four placebo-controlled parallel-group trials ranging from 12 to 52 weeks of treatment duration in adult patients (aged 18 to 75 years) with asthma. The safety data described below are based on one 1-year, two 6-month and one 12-week randomized, double-blind, placebo-controlled trials in a total of 2849 asthma patients on background treatment of at least ICS or ICS and long-acting beta agonist (ICS/LABA). Of these patients, 787 were treated with SPIRIVA RESPIMAT at the recommended dose of 2.5 mcg once-daily; 59.7% were female and 47.5% were Caucasian with a mean age of 43.7 years and a mean post-bronchodilator percent predicted forced expiratory volume in 1 second (FEV1) of 90.0% at baseline.
Table 2 shows all adverse reactions that occurred with an incidence of >2% in the SPIRIVA RESPIMAT 2.5 mcg treatment group, and a higher incidence rate on SPIRIVA RESPIMAT 2.5 mcg than on placebo.
Table 2 Number (Percentage) of Asthma Patients Exposed to SPIRIVA RESPIMAT 2.5 mcg with Adverse Reactions >2% (and Higher than Placebo): Pooled Data from 4 Adult Clinical Trials with Treatment Periods Ranging between 12 and 52 Weeks in Asthma Patients 

Body System (Reaction)* SPIRIVA RESPIMAT 2.5 mcg
[n=787]
Placebo
[n=735]
Respiratory, Thoracic, and Mediastinal Disorders    
  Pharyngitis 125 (15.9) 91 (12.4)
  Sinusitis 21 (2.7) 10 (1.4)
  Bronchitis 26 (3.3) 10 (1.4)
Nervous System Disorders    
  Headache 30 (3.8) 20 (2.7)
*Adverse reactions include a grouping of similar terms
Other reactions that occurred in the SPIRIVA RESPIMAT 2.5 mcg group at an incidence of 1% to 2% and at a higher incidence rate on SPIRIVA RESPIMAT 2.5 mcg than on placebo included: Nervous system disorders: dizziness; Gastrointestinal disorders: oropharyngeal, candidiasis, diarrhea; Respiratory system disorders (Upper): cough, rhinitis allergic; Renal and urinary disorders: urinary tract infection; General disorders and administration site conditions: pyrexia; and Vascular disorders: hypertension.
Less Common Adverse Reactions
Among the adverse reactions observed in the clinical trials with an incidence of 0.5% to <1% and at a higher incidence rate on SPIRIVA RESPIMAT 2.5 mcg than on placebo were: palpitations, dysphonia, acute tonsillitis, tonsillitis, rhinitis, herpes zoster, gastroesophageal reflux disease, oropharyngeal discomfort, abdominal pain upper, insomnia, hypersensitivity (including immediate reactions), angioedema, dehydration, arthralgia, muscle spasms, pain in extremity, chest pain, hepatic function abnormal, liver function test abnormal.
Adolescent Patients Aged 12 to 17 years
SPIRIVA RESPIMAT 2.5 mcg has been compared to placebo in two placebo-controlled parallel-group trials ranging from 12 to 48 weeks of treatment duration in adolescent patients with asthma. The safety data described below are based on one 1-year and one 12-week double-blind, placebo-controlled trials in a total of 789 adolescent asthma patients on background treatment of at least ICS or ICS plus one or more controller. Of these patients, 252 were treated with SPIRIVA RESPIMAT at the recommended dose of 2.5 mcg once-daily; 63.9% were male and 95.6% were Caucasian with a mean age of 14.3 years and a mean post-bronchodilator percent predicted FEV1 of 98.3% at baseline. The adverse reaction profile for adolescent patients with asthma was comparable to that observed in adult patients with asthma.
SPIRIVA RESPIMAT 5 mcg also has been compared to placebo in seven placebo-controlled parallel-group trials ranging from 12 to 52 weeks of treatment duration in 4149 adult patients (aged 18 to 75 years) with asthma and in two placebo-controlled parallel-group trials ranging from 12 to 48 weeks of treatment duration in 789 adolescent patients (1370 adults and 264 adolescents receiving SPIRIVA RESPIMAT 5 mcg once-daily). The adverse reaction profile for SPIRIVA RESPIMAT 5 mcg in patients with asthma was comparable to that observed with SPIRIVA RESPIMAT 2.5 mcg in patients with asthma.
6.3 Postmarketing Experience
In addition to the adverse reactions observed during the SPIRIVA RESPIMAT clinical trials in COPD, the following adverse reactions have been identified during the worldwide use of SPIRIVA RESPIMAT 5 mcg and another tiotropium formulation, SPIRIVA® HandiHaler® (tiotropium bromide inhalation powder): glaucoma, intraocular pressure increased, vision blurred, atrial fibrillation, tachycardia, supraventricular tachycardia, bronchospasm, glossitis, stomatitis, dehydration, insomnia, hypersensitivity (including immediate reactions), and urticaria.
7 DRUG INTERACTIONS
7.1 Concomitant Respiratory Medications
SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions.
7.2 Anticholinergics
There is potential for an additive interaction with concomitantly used anticholinergic medications. Therefore, avoid coadministration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs as this may lead to an increase in anticholinergic adverse effects [see Warnings and Precautions (5.4, 5.5) and Adverse Reactions (6)].
8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
Teratogenic Effects: Pregnancy Category C.
There are no adequate and well-controlled studies in pregnant women. SPIRIVA RESPIMAT should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
No evidence of structural alterations was observed in rats and rabbits at approximately 790 and 8 times the maximum recommended human daily inhalation dose (MRHDID), respectively (on a mcg/m2 basis at maternal inhalation doses of 1471 and 7 mcg/kg/day in rats and rabbits, respectively). However, in rats, tiotropium caused fetal resorption, litter loss, decreases in the number of live pups at birth and the mean pup weights, and a delay in pup sexual maturation at inhalation tiotropium doses of approximately 40 times the MRHDID (on a mcg/m2 basis at a maternal inhalation dose of 78 mcg/kg/day). In rabbits, tiotropium caused an increase in post-implantation loss at an inhalation dose of approximately 430 times the MRHDID (on a mcg/m2 basis at a maternal inhalation dose of 400 mcg/kg/day). Such effects were not observed at approximately 5 and 95 times the MRHDID, respectively (on a mcg/m2 basis at inhalation doses of 9 and 88 mcg/kg/day in rats and rabbits, respectively).
8.2 Labor and Delivery
The safety and effectiveness of SPIRIVA RESPIMAT has not been studied during labor and delivery.
8.3 Nursing Mothers
Clinical data from nursing women exposed to tiotropium are not available. Based on lactating rodent studies, tiotropium is excreted into breast milk. It is not known whether tiotropium is excreted in human milk, but because many drugs are excreted in human milk and given these findings in rats, caution should be exercised if SPIRIVA RESPIMAT is administered to a nursing woman.
8.4 Pediatric Use
The safety and efficacy of SPIRIVA RESPIMAT 2.5 mcg have been established in adolescents (aged 12 to 17 years) with asthma in 3 clinical trials up to 1 year in duration [see Clinical Studies (14.2)]. In the 3 clinical trials, 327 patients aged 12 to 17 years with asthma were treated with SPIRIVA RESPIMAT 2.5 mcg. Patients in this age group demonstrated efficacy results similar to those observed in patients aged 18 years and older with asthma. The adverse drug reactions profile for this age group was comparable to that observed for patients aged 18 years and older with asthma. Based on available data, no adjustment of dosage of SPIRIVA RESPIMAT in adolescent patients with asthma is warranted [see Clinical Pharmacology (12.3)]. The safety and efficacy of SPIRIVA RESPIMAT have not been established in pediatric patients less than 12 years of age.
8.5 Geriatric Use
Based on available data, no adjustment of SPIRIVA RESPIMAT dosage in geriatric patients is warranted [see Clinical Pharmacology (12.3)].
Thirty nine percent of SPIRIVA RESPIMAT clinical trial patients with COPD were between 65 and 75 years of age and 14% were greater than or equal to 75 years of age. Approximately seven percent of SPIRIVA RESPIMAT clinical trial patients with asthma were greater than or equal to 65 years of age. The adverse drug reaction profiles were similar in the older population compared to the patient population overall.
8.6 Renal Impairment
Patients with moderate to severe renal impairment (creatinine clearance of <60 mL/min) treated with SPIRIVA RESPIMAT should be monitored closely for anticholinergic side effects [see Dosage and Administration (2), Warnings and Precautions (5.6), and Clinical Pharmacology (12.3)].
8.7 Hepatic Impairment
The effects of hepatic impairment on the pharmacokinetics of tiotropium were not studied.
10 OVERDOSAGE
High doses of tiotropium may lead to anticholinergic signs and symptoms. However, there were no systemic anticholinergic adverse effects following a single inhaled dose of up to 282 mcg tiotropium dry powder in 6 healthy volunteers. Dry mouth/throat and dry nasal mucosa occurred in a dose-dependent [10-40 mcg daily] manner, following 14-day dosing of up to 40 mcg tiotropium bromide inhalation solution in healthy subjects.
Treatment of overdosage consists of discontinuation of SPIRIVA RESPIMAT together with institution of appropriate symptomatic and/or supportive therapy.
11 DESCRIPTION
The active component of SPIRIVA RESPIMAT is tiotropium. The drug substance, tiotropium bromide monohydrate, is an anticholinergic with specificity for muscarinic receptors. It is chemically described as (1α, 2ß, 4ß, 5α, 7ß)-7-[(Hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4] nonane bromide monohydrate. It is a synthetic, non-chiral, quaternary ammonium compound. Tiotropium bromide is a white or yellowish white powder. It is sparingly soluble in water and soluble in methanol.
The structural formula is:


Tiotropium bromide (monohydrate) has a molecular mass of 490.4 and a molecular formula of C19H22NO4S2Br • H2O.
The drug product, SPIRIVA RESPIMAT, is composed of a sterile, aqueous solution of tiotropium bromide filled into a 4.5 mL plastic container crimped into an aluminum cylinder (SPIRIVA RESPIMAT cartridge) for use with the SPIRIVA RESPIMAT inhaler. Excipients include water for injection, edetate disodium, benzalkonium chloride and hydrochloric acid. The SPIRIVA RESPIMAT cartridge is only intended for use with the SPIRIVA RESPIMAT inhaler. The RESPIMAT inhaler is a hand held, pocket sized oral inhalation device that uses mechanical energy to generate a slow moving aerosol cloud of medication from a metered volume of the drug solution.
When used with the SPIRIVA RESPIMAT inhaler, each cartridge containing 4 grams of sterile aqueous solution delivers 60 (or 28) metered actuations after preparation for use, the equivalent of 30 days’ (or 14 days’) medication when used as two actuations once a day. Each dose (one dose equals two actuations) from the SPIRIVA RESPIMAT inhaler delivers 2.5 mcg or 5 mcg of tiotropium in 22.1 mcL from the mouthpiece. As with all inhaled drugs, the actual amount of drug delivered to the lung may depend on patient factors, such as the coordination between the actuation of the inhaler and inspiration through the delivery system. The duration of inspiration should be at least as long as the spray duration (1.5 seconds).
Prior to first use, the SPIRIVA RESPIMAT cartridge is inserted into the SPIRIVA RESPIMAT inhaler and the unit is primed. When using the unit for the first time, patients are to actuate the inhaler toward the ground until an aerosol cloud is visible and then repeat the process three more times. The unit is then considered primed and ready for use. If not used for more than 3 days, patients are to actuate the inhaler once to prepare the inhaler for use. If not used for more than 21 days, patients are to actuate the inhaler until an aerosol cloud is visible and then repeat the process three more times to prepare the inhaler for use [see Patient Counseling Information (17)].
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
Tiotropium is a long-acting, antimuscarinic agent, which is often referred to as an anticholinergic. It has similar affinity to the subtypes of muscarinic receptors, M1 to M5. In the airways, it exhibits pharmacological effects through inhibition of M3-receptors at the smooth muscle leading to bronchodilation. The competitive and reversible nature of antagonism was shown with human and animal origin receptors and isolated organ preparations. In preclinical in vitro as well as in vivo studies, prevention of methacholine-induced bronchoconstriction effects was dose-dependent and lasted longer than 24 hours. The bronchodilation following inhalation of tiotropium is predominantly a site-specific effect.
12.2 Pharmacodynamics
Cardiac Electrophysiology
In a multicenter, randomized, double-blind trial using tiotropium dry powder for inhalation that enrolled 198 patients with COPD, the number of subjects with changes from baseline-corrected QT interval of 30 to 60 msec was higher in the SPIRIVA group as compared with placebo. This difference was apparent using both the Bazett (QTcB) [20 (20%) patients vs. 12 (12%) patients] and Fredericia (QTcF) [16 (16%) patients vs. 1 (1%) patient] corrections of QT for heart rate. No patients in either group had either QTcB or QTcF of >500 msec. Other clinical trials with SPIRIVA did not detect an effect of the drug on QTc intervals.
The effect of tiotropium dry powder for inhalation on QT interval was also evaluated in a randomized, placebo- and positive-controlled crossover study in 53 healthy volunteers. Subjects received tiotropium inhalation powder 18 mcg, 54 mcg (3 times the recommended dose), or placebo for 12 days. ECG assessments were performed at baseline and throughout the dosing interval following the first and last dose of study medication. Relative to placebo, the maximum mean change from baseline in study-specific QTc interval was 3.2 msec and 0.8 msec for tiotropium inhalation powder 18 mcg and 54 mcg, respectively. No subject showed a new onset of QTc >500 msec or QTc changes from baseline of ≥60 msec.
12.3 Pharmacokinetics
Tiotropium is administered as an inhalation spray. Some of the pharmacokinetic data described below were obtained with higher doses than recommended for therapy. A dedicated pharmacokinetic study in patients with COPD evaluating once-daily tiotropium delivered from the RESPIMAT inhaler (5 mcg) and as inhalation powder (18 mcg) from the HandiHaler resulted in a similar systemic exposure between the two products.
Absorption
Following inhalation of the solution by young healthy volunteers, urinary excretion data suggests that approximately 33% of the inhaled dose reaches the systemic circulation. Oral solutions of tiotropium have an absolute bioavailability of 2% to 3%. Food is not expected to influence the absorption of tiotropium for the same reason. Following 4-week SPIRIVA RESPIMAT once daily dosing, maximum tiotropium plasma concentrations were observed 5-7 minutes after inhalation in COPD and asthma patients.
Distribution
The drug has a plasma protein binding of 72% and shows a volume of distribution of 32 L/kg after an intravenous dose to young healthy volunteers. Local concentrations in the lung are not known, but the mode of administration suggests substantially higher concentrations in the lung. Studies in rats have shown that tiotropium does not penetrate the blood-brain barrier.
Elimination
Metabolism
The extent of metabolism is small. This is evident from a urinary excretion of 74% of unchanged substance after an intravenous dose to young healthy volunteers. Tiotropium, an ester, is nonenzymatically cleaved to the alcohol N-methylscopine and dithienylglycolic acid, neither of which binds to muscarinic receptors.
In vitro experiments with human liver microsomes and human hepatocytes suggest that a fraction of the administered dose (74% of an intravenous dose is excreted unchanged in the urine, leaving 25% for metabolism) is metabolized by cytochrome P450-dependent oxidation and subsequent glutathione conjugation to a variety of Phase II metabolites. This enzymatic pathway can be inhibited by CYP450 2D6 and 3A4 inhibitors, such as quinidine, ketoconazole, and gestodene. Thus, CYP450 2D6 and 3A4 are involved in the metabolic pathway that is responsible for the elimination of a small part of the administered dose. In vitro studies using human liver microsomes showed that tiotropium in supra-therapeutic concentrations does not inhibit CYP450 1A1, 1A2, 2B6, 2C9, 2C19, 2D6, 2E1, or 3A4.
Excretion
The terminal half-life of tiotropium in COPD and asthma patients following once daily inhalation is 25 and 44 hours, respectively. Total clearance was 880 mL/min after an intravenous dose in young healthy volunteers. Intravenously administered tiotropium bromide is mainly excreted unchanged in urine (74%). Following 21-day once daily inhalation of 5 mcg of the solution by patients with COPD, 24-hour urinary excretion is 18.6% (0.93 mcg) of the dose. The renal clearance of tiotropium exceeds the creatinine clearance, indicating secretion into the urine. In comparison, 12.8% (0.32 mcg) of the dose was excreted unchanged in the urine over 24 hours at steady state after inhalation of 2.5 mcg in patients with asthma. After chronic once-daily inhalation by COPD and asthma patients, pharmacokinetic steady-state was reached by day 7 with no accumulation thereafter.
Specific Populations
Geriatric Patients
As expected for all predominantly renally excreted drugs, advancing age was associated with a decrease of tiotropium renal clearance (347 mL/min in COPD patients <65 years to 275 mL/min in COPD patients ≥65 years). This did not result in a corresponding increase in AUC0-6,ss and Cmax,ss values following inhalation of the solution. Exposure to tiotropium was not found to differ with age in patients with asthma.
Pediatric Patients
The exposure to tiotropium was not found to differ between adolescents (aged 12 to 17 years) and adults with asthma.
Renal Impairment
Following 4-week SPIRIVA RESPIMAT 5 mcg once daily dosing in patients with COPD, mild renal impairment (creatinine clearance 60-90 mL/min) resulted in 23% higher AUC0-6,ss and 17% higher Cmax,ss values; moderate renal impairment (creatinine clearance 30-60 mL/min) resulted in 57% higher AUC0-6,ss and 31% higher Cmax,ss values compared to COPD patients with normal renal function (creatinine clearance >90 mL/min). The influence of mild or moderate renal impairment on the systemic exposure to SPIRIVA RESPIMAT 2.5 mcg in patients with asthma was similar to what has been described for COPD above. There lacks sufficient data of tiotropium exposure in patients with severe renal impairment (creatinine clearance <30 mL/min) following inhalation of SPIRIVA RESPIMAT. However AUC0-4 and Cmax were 94% and 52% higher, respectively, in patients with severe renal impairment following intravenous infusion of tiotropium bromide.
Hepatic Impairment
The effects of hepatic impairment on the pharmacokinetics of tiotropium were not studied.
Drug Interactions
An interaction study with tiotropium (14.4 mcg intravenous infusion over 15 minutes) and cimetidine 400 mg three times daily or ranitidine 300 mg once-daily was conducted. Concomitant administration of cimetidine with tiotropium resulted in a 20% increase in the AUC0-4h, a 28% decrease in the renal clearance of tiotropium and no significant change in the Cmax and amount excreted in urine over 96 hours. Co-administration of tiotropium with ranitidine did not affect the pharmacokinetics of tiotropium.
Common concomitant medications (LABA, ICS) used by patients with COPD were not found to alter the exposure to tiotropium. Similarly, common concomitant medications (LABA, ICS+LABA combinations, oral corticosteroids and leukotriene modifiers) used by patients with asthma were not found to alter the exposure to tiotropium.
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
No evidence of tumorigenicity was observed in a 104-week inhalation study in rats at tiotropium doses up to 59 mcg/kg/day, in an 83-week inhalation study in female mice at doses up to 145 mcg/kg/day, and in a 101‑week inhalation study in male mice at doses up to 2 mcg/kg/day. These doses correspond to approximately 30, 40, and 0.5, times the maximum recommended human daily inhalation dose (MRHDID) on a mcg/m2 basis, respectively.
Tiotropium bromide demonstrated no evidence of mutagenicity or clastogenicity in the following assays: the bacterial gene mutation assay, the V79 Chinese hamster cell mutagenesis assay, the chromosomal aberration assays in human lymphocytes in vitro and mouse micronucleus formation in vivo, and the unscheduled DNA synthesis in primary rat hepatocytes in vitro assay.
In rats, decreases in the number of corpora lutea and the percentage of implants were noted at inhalation tiotropium doses of 78 mcg/kg/day or greater (approximately 40 times the MRHDID on a mcg/m2 basis). No such effects were observed at 9 mcg/kg/day (approximately 5 times the MRHDID on a mcg/m2 basis). The fertility index, however, was not affected at inhalation doses up to 1689 mcg/kg/day (approximately 910 times the MRHDID on a mcg/m2 basis).
14 CLINICAL STUDIES
14.1 Chronic Obstructive Pulmonary Disease
The efficacy of SPIRIVA RESPIMAT compared to placebo was evaluated in 6 clinical trials: one dose-ranging trial and 5 confirmatory trials (Trials 1-5). In addition, SPIRIVA RESPIMAT was compared to SPIRIVA HandiHaler in a long-term active-controlled trial in COPD (Trial 6).
Dose-Ranging Trial
Dose selection for the Phase III clinical program was supported by a 3-week randomized, double-blind, placebo and active-controlled, parallel group trial in 202 COPD patients. A total of five doses of tiotropium RESPIMAT (1.25 to 20 mcg) were evaluated compared to placebo. Results demonstrated numerical improvements in FEV1 at all doses compared to placebo. The difference in trough FEV1 from placebo for the 1.25, 2.5, 5, 10 and 20 mcg once daily doses were 0.08 L (95% CI -0.03, 0.20), 0.03 L (-0.08, 0.15), 0.13 L (0.02, 0.25), 0.11 L (-0.004, 0.224), and 0.13 L (0.01, 0.24), respectively. Based on these results, the 5 and 10 mcg doses were further evaluated in the confirmatory COPD trials.
Confirmatory Trials
A total of 6614 COPD patients (2801 receiving SPIRIVA RESPIMAT 5 mcg and 2798 receiving placebo) were studied in the five confirmatory trials of SPIRIVA RESPIMAT. Trials 1 and 2 were 12-week, randomized, double-blind, placebo- and active- (ipratropium) controlled trials that evaluated bronchodilation. Trials 3-5 were 48-week, randomized, double-blind, placebo-controlled, trials that evaluated bronchodilation and effects on COPD exacerbations. Trials 1-4 included both the tiotropium RESPIMAT 5 mcg and 10 mcg doses, whereas Trial 5 included only the 5 mcg dose. These trials enrolled patients who had a clinical diagnosis of COPD, were 40 years of age or older, had a history of smoking greater than 10 pack-years, had an FEV1 less than or equal to 60% of predicted and a ratio of FEV1/FVC of less than or equal to 0.7. All treatments were administered once-daily in the morning. Change from baseline in trough FEV1 was a primary endpoint in all trials. Trials 3-5 included COPD exacerbations as primary endpoints.
Baseline patient characteristics were similar across the five individual confirmatory trials, except for race in Trial 5 in which there were more Asian patients (30%) compared to other trials (<1%). The mean age ranged from 62 to 66 years. Most patients were male (64-78%), ex-smokers (57-65%) and Caucasian (69-99%). Mean pre-bronchodilator FEV1 was between 1.03 and 1.26 L with a mean FEV1/FVC ratio of 42-50%. Except for LABAs and other inhaled anticholinergic agents, other pulmonary medications were allowed as concomitant therapy in Trials 1-4. LABA use was permitted in Trial 5.
Effect on Lung Function
SPIRIVA RESPIMAT 5 mcg demonstrated significant improvement in trough FEV1 compared to placebo in all 5 confirmatory trials (Table 3). The change from baseline in trough FEV1 over time from Trial 4 is depicted in Figure 1 and is representative of the other two 48-week trials. In Trials 3 and 4 patients treated with SPIRIVA RESPIMAT 5 mcg also used less rescue medication compared to patients on placebo.
Table 3 Mean Change from Baseline in Trough FEV1 (L) at End of Treatment 

Trial SPIRIVA
RESPIMAT
5 mcg
N
Placebo
N
Trough FEV1 (L) at End of Treatment
Difference from placebo (95% CI)
Trial 1† 85 87 0.11 (0.04, 0.18)
Trial 2† 90 84 0.13 (0.07, 0.18)
Trial 3‡ 326 296 0.14 (0.10, 0.18)
Trial 4‡ 324 307 0.11 (0.08, 0.15)
Trial 5‡ 1889 1870 0.10 (0.09, 0.12)
at week 12
at week 48
Figure 1 Trough FEV1 Change from Baseline over 48 Weeks (Trial 4), SPIRIVA RESPIMAT 5 mcg


Exacerbations
Trials 3, 4, and 5 also evaluated the effect of SPIRIVA RESPIMAT 5 mcg on COPD exacerbations. For Trials 3 and 4, a pooled analysis of exacerbation rate per patient year was pre-specified as a primary endpoint, while the primary endpoint for Trial 5 was time to first exacerbation. Trial 5 also included exacerbation rate per patient year as a secondary endpoint. Exacerbations were defined as a complex of respiratory events/symptoms with a duration of ≥3 days with ≥2 of the following (increase of symptoms or new onset): shortness of breath/dyspnea/shallow, rapid breathing; sputum production (volume); occurrence of purulent sputum; cough; wheezing; chest tightness.
In the pooled analysis of Trials 3 and 4, SPIRIVA RESPIMAT 5 mcg significantly reduced the number of COPD exacerbations compared to placebo with 0.78 exacerbations/patient year versus 1.0 exacerbations/patient year, respectively, with a rate ratio of 0.78 (95% CI 0.67, 0.92). Time to first exacerbation was also delayed in SPIRIVA RESPIMAT 5 mcg patients. For Trial 5, in addition to the definition above, an exacerbation also had to result in a change in or requirement of treatment. In Trial 5, treatment with SPIRIVA RESPIMAT 5 mcg delayed the time to first COPD exacerbation compared to treatment with placebo [hazard ratio of 0.69 (95% CI 0.63, 0.77)]. Consistent with the pooled analysis of Trials 3 and 4, for Trial 5, exacerbation rate was also lower in SPIRIVA RESPIMAT 5 mcg compared to placebo. In Trial 5, SPIRIVA RESPIMAT 5 mcg also reduced the risk of COPD exacerbation-related hospitalization (HR = 0.73; 95% CI = 0.59, 0.90) compared to placebo.
Long-term Active-Controlled Mortality Trial
Survival
In a pooled analysis of SPIRIVA RESPIMAT placebo-controlled clinical trials with complete vital status (mortality) follow-up, including the three 48-week trials (Trial 3, 4, and 5) and one 24-week placebo-controlled trial, 68 deaths (Incidence Rate 2.64 deaths per 100 patient years) were observed in the SPIRIVA RESPIMAT 5 mcg treatment group compared to 51 deaths (Incidence Rate 1.98 deaths per 100 patient years) in those treated with placebo. In a 4-year, randomized, double-blind, placebo-controlled, multicenter clinical trial of tiotropium bromide inhalation powder (SPIRIVA HandiHaler) in 5992 COPD patients a similar incidence rate of death had been observed between SPIRIVA HandiHaler and placebo treated groups.
For clarification of the observed difference in fatal events, a long-term, randomized, double-blind, double dummy, active-controlled trial with an observation period up to 3 years was conducted to evaluate the risk of all-cause mortality associated with the use of SPIRIVA RESPIMAT compared to SPIRIVA HandiHaler (Trial 6). The objective of this trial was to rule out a relative excess mortality risk of 25% for SPIRIVA RESPIMAT versus SPIRIVA HandiHaler. The primary endpoints were all-cause mortality and time to first COPD exacerbation. Trial 6 also included a lung function sub-study which measured trough FEV1 measured every 24 weeks for 120 weeks (461 patients receiving SPIRIVA RESPIMAT 5 mcg, 445 patients receiving SPIRIVA HandiHaler).
In Trial 6, 5711 patients received SPIRIVA RESPIMAT 5 mcg and 5694 patients received SPIRIVA HandiHaler. All patients were followed for vital status (mortality) at the end of the trial. At baseline, patient characteristics were balanced between the two treatment arms. The mean age was 65 years and approximately 70% of subjects were male. Approximately, 82% of patients were Caucasian, 14% were Asian, and 2% were Black. Mean post-bronchodilator FEV1 was 1.34 L with a mean FEV1/FVC ratio of 50%. The majority of patients were GOLD II or III (48% and 40%, respectively).
The vital status was confirmed in 99.7% of patients. The median exposure to treatment was 835 days for both treatment groups. All-cause mortality was similar between SPIRIVA RESPIMAT 5 mcg and SPIRIVA HandiHaler with an estimated hazard ratio of 0.96 [(95% CI of (0.84 to 1.09), Table 4].
Table 4 All-cause Mortality of SPIRIVA RESPIMAT vs SPIRIVA HandiHaler (Trial 6) 

SPIRIVA RESPIMAT 5 mcg
(N = 5711)
SPIRIVA HandiHaler
(N = 5694)
Number (%) of Deaths 423 (7.4) 439 (7.7)
Incidence Rate per 100 patient years 3.22 3.36
HR (95% CI)a 0.96 (0.84, 1.09)
a Hazard ratios were estimated from a Cox proportional hazard model.
Cause of death was adjudicated by a blinded, independent committee. Cardiovascular deaths included cardiac death, sudden cardiac death, and sudden death; as well as fatal events caused by a cardiac disorder, vascular disorder, or stroke. There were 113 patients (2%) treated with SPIRIVA RESPIMAT 5 mcg who had cardiovascular deaths compared to 101 (2%) patients treated with SPIRIVA HandiHaler. Of the cardiovascular deaths, 11 (0.2%) and 3 (0.1%) deaths were due to myocardial infarction in SPIRIVA RESPIMAT 5 mcg patients and SPIRIVA HandiHaler patients, respectively. For cardiac deaths, sudden cardiac death, and sudden death, there were a total of 69 (1.2%) and 68 (1.2%) deaths in SPIRIVA RESPIMAT 5 mcg patients and SPIRIVA HandiHaler patients, respectively.
Effect on Lung Function and Exacerbations
In the lung function sub-study the effect of SPIRIVA RESPIMAT 5 mcg on trough FEV1 over 120 weeks was similar to SPIRIVA HandiHaler with a mean difference of -0.010 L (95% CI -0.038 to 0.018 L).
Trial 6 also included time to first exacerbation as a co-primary endpoint (exacerbations defined as in Trials 3-5). SPIRIVA RESPIMAT 5 mcg failed to demonstrate superiority to SPIRIVA HandiHaler with a similar time to first COPD exacerbation between treatment groups [hazard ratio of 0.98 (95% CI 0.93 to 1.03)].
14.2 Asthma
The SPIRIVA RESPIMAT clinical development program included five 4-week to 8-week cross-over design trials and seven 12-week to 48-week parallel-arm design trials in adult and adolescent (aged 12 to 17 years) patients with asthma symptomatic on at least ICS. In all trials, SPIRIVA RESPIMAT was administered on a background of ICS therapy.
Dose Selection
Dose selection for the confirmatory trials was based on three randomized, double-blind, placebo-controlled, 4-week to 8-week, cross-over trials in 256 adult patients and 105 adolescent (age 12 to 17 years) patients that assessed doses ranging from 1.25 mcg to 10 mcg once daily. Results demonstrated numerical improvements in FEV1 at all doses compared to placebo; however, across the trials, the response was not dose-ordered. For adult patients, in the 4-week trial the difference in peak FEV1 within 3 h post-dosing (peak FEV1, 0-3h) from placebo for the tiotropium RESPIMAT 1.25, 2.5, and 5 mcg doses were 0.138 L (95% CI 0.090, 0.186), 0.128 L (0.080, 0.176), and 0.188 L (0.140, 0.236), respectively. For adolescent patients, the difference in peak FEV1, 0-3h from placebo for the tiotropium RESPIMAT 1.25, 2.5, and 5 mcg doses were 0.067 L (95% CI −0.005, 0.138), 0.057 L (−0.021, 0.135), and 0.113 L (0.036, 0.190), respectively. The 10 mcg dose offered no substantial benefit over lower doses and resulted in more systemic anticholinergic side effects (e.g., dry mouth).
The two dose regimen trials in adults with asthma were randomized, double-blind, 4-week, cross-over trials comparing tiotropium RESPIMAT 2.5 mcg twice-daily with 5 mcg once-daily. 24-hour FEV1 results demonstrated comparable treatment effects for twice-daily and once-daily dosing.
12-week to 48-week Parallel-Arm Design Trials in Adults
The program for persistent asthma in adult patients included one 12-week (Trial 1), two replicate 24-week (Trials 2 and 3), and two replicate 48-week (Trials 4 and 5) randomized, double-blind, placebo-controlled trials in a total of 3476 asthma patients (673 receiving SPIRIVA RESPIMAT 2.5 mcg once-daily, 1128 receiving SPIRIVA RESPIMAT 5 mcg once-daily, 541 receiving salmeterol 50 mcg twice daily, and 1134 receiving placebo) on background treatment of at least ICS. Trial 1 evaluated three treatments: SPIRIVA RESPIMAT 2.5 mcg once-daily, SPIRIVA RESPIMAT 5 mcg once-daily, and placebo. Trials 2 and 3 evaluated four treatments: SPIRIVA RESPIMAT 2.5 mcg once-daily, SPIRIVA RESPIMAT 5 mcg once-daily, salmeterol 50 mcg twice daily, and placebo. Trials 4 and 5 evaluated two treatments: SPIRIVA RESPIMAT 5 mcg once-daily and placebo. All trials enrolled patients who had a diagnosis of asthma, were 18 to 75 years of age, and were not current smokers. Patients enrolled in Trials 4 and 5 were required to have airway obstruction that was not fully reversible (post-bronchodilator FEV1/FVC, 0.70). The majority of the 3476 patients in the adult asthma trials were female (60%), Caucasian (61%) or Asian (31%), and had never smoked (81%) with a mean age of 46 years. The patient characteristics for the 12 week to 48 week trials in adult patients with asthma are summarized in Table 5.
Table 5 Summary of Baseline Patient Characteristics, Adult Confirmatory Studies 

Adults, 18 yrs and older
Trial 1 Trial 2 Trial 3 Trial 4 Trial 5
Demographics
Mean age in years (range) 42.9 (18 – 74) 43.3 (18 – 75) 42.9 (18 – 75) 53.4 (18 – 75) 52.5 (19 – 75)
Mean duration of asthma (years) 16.2 21.7 21.8 31.5 29.1
Smoking status, ex-smoker (%) 18 14 19 22 26
Laboratory (median)
Absolute eosinophils (109/L) 0.33 0.36 0.35 0.35 0.38
Total IgE (microgram/L) 536 638 641 601 449
Pulmonary function test (mean)
Pre-bronchodilator FEV1 (L) 2.30 2.18 2.21 1.55 1.59
Reversibility (%) 24.8 22.8 22.0 15.4 15.0
Absolute reversibility (mL) 556 488 477 215 218
Post-bronchodilator FEV1/FVC (%) 74 72 72 60 59
The primary efficacy endpoint in Trial 1 was change from pre-treatment baseline in peak FEV1, 0-3h at week 12. The co-primary efficacy endpoints in Trials 2 and 3 were change from pre-treatment baseline in peak FEV1, 0-3 hr and change from pre-treatment baseline in trough FEV1 at week 24. Additional efficacy measures included asthma exacerbation, Asthma Control Questionnaire (ACQ), and Asthma Quality of Life Questionnaire (AQLQ).
For Trials 1, 2, and 3, SPIRIVA RESPIMAT 2.5 mcg showed statistically significant improvements in lung function over placebo when used in addition to background treatment of ICS (Table 6).
Table 6 Differences from Placebo in Peak FEV1, 0-3 and Trough FEV1, Adult Confirmatory Studies at Primary Endpoint Time Evaluation 

Treatment
(Duration)
ICS Background
Treatment
b,c
Treatment in
mcg/day
n Peak FEV1, 0-3 hr, in L a Trough FEV1 , in L a
Δ from
baseline
Difference from placebo Δ from
baseline
Difference from placebo
Mean 95% CI Mean 95% CI
Adult patients, age 18 years and older
Trial 1
(12 weeks)

Low dose ICS
SPIRIVA RESPIMAT 2.5 mcg
Placebo
154
155
0.29
0.13
0.16 0.09, 0.23 0.13
0.02
0.11 0.04, 0.18
Trial 2
(24 weeks)

Medium dose ICS
SPIRIVA RESPIMAT 2.5 mcg
Salmeterol 100 mcg
Placebo
259
271
265
0.29
0.27
0.05
0.24
0.21
0.18, 0.29
0.16, 0.27
0.15
0.09
-0.03
0.19
0.12
0.13, 0.24
0.06, 0.18
Trial 3
(24 weeks)

Medium dose ICS
SPIRIVA RESPIMAT 2.5 mcg
Salmeterol 100 mcg
Placebo
256
264
253
0.29
0.25
0.08
0.21
0.18
0.16, 0.26
0.12, 0.23
0.16
0.09
-0.01
0.18
0.11
a Means adjusted for treatment, center/country, visit, visit*treatment, baseline, baseline*visit.
b Additional asthma medications allowed in stable doses prior to and throughout the trials.
c Low dose ICS = 200–400 mcg budesonide-equivalent. Medium dose ICS = 400–800 mcg budesonide-equivalent.
Trials 1, 2, and 3 also included a SPIRIVA RESPIMAT 5 mcg once daily treatment arm.  In these asthma trials, the FEV1 response (change from baseline for tiotropium compared to placebo) was generally lower for the 5 mcg dose compared to the 2.5 mcg dose. The peak FEV1, 0-3hr response was 16% to 20% lower for the 5 mcg dose compared to the 2.5 mcg dose in all three trials, and, the trough FEV1 response was 11% higher for the 5 mcg dose compared to the 2.5 mcg dose for one trial (Trial 1) and 18% and 24% lower for the 5 mcg dose compared to the 2.5 mcg dose for the other two trials (Trials 2 and 3).
Improvements in morning and evening peak expiratory flow (PEF) were consistent with the observed FEV1 treatment response. Examination of age, gender, smoking history, and serum IgE level subgroups did not identify differences in response among these subgroups.
The improvement of lung function compared to placebo was maintained for 24 hours (Figure 2). The bronchodilator effects of SPIRIVA RESPIMAT 2.5 mcg were apparent after first dose; however, maximum bronchodilator effect took up to 4 to 8 weeks to be achieved.
Figure 2 FEV1 Response over 24-Hours following 24-Weeks of Treatment, Trial 3


Asthma exacerbation was assessed in Trials 2 and 3 over the 24-week treatment periods. An asthma exacerbation was defined as an episode of progressive increase in ≥1 asthma symptom(s), such as shortness of breath, cough, wheezing, chest tightness or some combination of these symptoms or a decrease of a patient's best morning PEF of 30% from a patient's mean morning PEF for ≥2 consecutive days that required the initiation or increase in treatment with systemic steroids for ≥3 days. Results of asthma exacerbation are shown in Table 7.
Table 7 Exacerbations in Patients on ICS over 24-Weeks

Trial 2 Trial 3
  SPIRIVA RESPIMAT 2.5 mcg (N=259)

Placebo

(N=265)

SPIRIVA RESPIMAT 2.5 mcg

(N=256)

Placebo

(N=253)

Number of patients with at least 1 event, n (%) 9 (3.5) 24 (9.1) 13 (5.1) 19 (7.5)
Rate of exacerbations per patient year
Mean rate of events 0.08 0.24 0.13 0.18

Comparison to Placebo,

Rate ratio (95% CI)

0.32 (0.20, 0.51)   0.70 (0.46, 1.08)  
Time to first asthma exacerbation

Comparison to Placebo,

Hazard ratio (95% CI)

0.37 (0.17, 0.80)   0.66 (0.33, 1.34)
Trials 2 and 3 also evaluated the rate of exacerbations and time to first asthma exacerbation for the SPIRIVA RESPIMAT 5 mcg dose. The rate of asthma exacerbations compared to placebo for SPIRIVA RESPIMAT 5 mcg was 0.78 (95% CI 0.55, 1.10) in Trial 2 and 0.76 (0.50, 1.16) in Trial 3. The hazard ratio for time to first asthma exacerbation for SPIRIVA RESPIMAT 5 mcg compared to placebo was 0.72 (95% CI 0.39, 1.35), in Trial 2 and 0.72 (0.36, 1.43) in Trial 3.
ACQ and AQLQ were assessed in Trials 2 and 3 at week 24. In Trial 2, the ACQ-7 (7 items) responder rate (defined as a change in score >0.5) for the SPIRIVA RESPIMAT 2.5 mcg treatment arm was 63% compared to 53% for placebo with an odds ratio of 1.47 (95% CI 1.02, 2.11). The ACQ-5 (derived from ACQ 7 by removing the FEV1 component and rescue bronchodilator component) results also had a similar trend. In Trial 2, the AQLQ responder rate (defined as a change in score >0.5) for the SPIRIVA RESPIMAT 2.5 mcg treatment arm was 58% compared to 50% for placebo with an odds ratio of 1.34 (95% CI 0.94, 1.93).
12-week and 48-week Parallel-Arm Design Trials in Adolescents 12-17 Years of Age
Efficacy in adolescents was based on partial extrapolation of efficacy in adults and two randomized, double-blind, placebo-controlled trials of 12 and 48 weeks duration in a total of 789 asthma patients 12 to 17 years of age (252 receiving SPIRIVA RESPIMAT 2.5 mcg once-daily, 264 receiving 5 mcg once-daily, and 273 receiving placebo). Both trials included SPIRIVA RESPIMAT 2.5 mcg and 5 mcg doses. The 12-week trial enrolled patients with severe asthma who were on background treatment of ICS plus one or more controller medications (e.g. LABA). The 48-week trial enrolled patients with moderate asthma on background treatment of at least ICS. The majority of the patients in the trials were male (63.4%), Caucasian (93.7%) and had never smoked (99.9%) with a mean age of 14.3 years.
The primary efficacy endpoint in both trials was change from pre-treatment baseline in peak FEV1, 0-3h. The primary endpoint evaluation for FEV1 was defined at week 24 for the 48-week trial and at end of the treatment period (week 12) for the 12-week trial. Given the demonstration of efficacy in the adult population, the results of the 2 trials support the efficacy of SPIRIVA RESPIMAT 2.5 mcg once daily in adolescent patients 12-17 years of age with asthma (mean difference in peak FEV1, 0-3h from placebo for SPIRIVA RESPIMAT 2.5 mcg were 0.13 L (95% CI 0.03, 0.23) and 0.11 (0.002, 0.22) for the 48-week and 12-week trials, respectively).
16 HOW SUPPLIED/STORAGE AND HANDLING
SPIRIVA RESPIMAT Inhalation Spray is supplied in a carton containing one SPIRIVA RESPIMAT cartridge and one SPIRIVA RESPIMAT inhaler.
The SPIRIVA RESPIMAT cartridge is provided as an aluminum cylinder with a tamper protection seal on the cap. The SPIRIVA RESPIMAT cartridge is only intended for use with the SPIRIVA RESPIMAT inhaler and should not be interchanged with any other RESPIMAT device delivered product.
The SPIRIVA RESPIMAT inhaler is a cylindrical shaped plastic inhalation device with a gray colored body and a clear base. The clear base is removed to insert the cartridge. The inhaler contains a dose indicator. The written information on the label of the gray inhaler body indicate that it is labeled for use with the SPIRIVA RESPIMAT cartridge.
SPIRIVA RESPIMAT Inhalation Spray is available in two dosage strengths, identified by dose delivered per actuation and by the color of the cap and associated container label: aqua represents 2.5 mcg per actuation; blue represents 1.25 mcg per actuation.
To deliver the recommended dosage for COPD:
SPIRIVA RESPIMAT Inhalation Spray 2.5 mcg/actuation 60 metered actuations(NDC 0597-0100-61)
SPIRIVA RESPIMAT Inhalation Spray 2.5 mcg/actuation 28 metered actuations(NDC 0597-0100-31) (institutional pack)
To deliver the recommended dosage for asthma:
SPIRIVA RESPIMAT Inhalation Spray 1.25 mcg/actuation 60 metered actuations(NDC 0597-0160-61)
SPIRIVA RESPIMAT Inhalation Spray 1.25 mcg/actuation 28 metered actuations(NDC 0597-0160-31) (institutional pack)
The SPIRIVA RESPIMAT cartridge for each strength has a net fill weight of 4 grams and when used with the SPIRIVA RESPIMAT inhaler, is designed to deliver the labeled number of metered actuations (60 or 28) after preparation for use; which is, respectively, equivalent to 30 or 14 days of medication when used according to the Instructions for Use. Each actuation from the SPIRIVA RESPIMAT inhaler delivers 1.25 or 2.5 mcg of tiotropium (equivalent to 1.562 or 3.124 mcg, respectively, of tiotropium bromide monohydrate) from the mouthpiece.
When the labeled number of actuations (60 or 28) has been dispensed from the inhaler, the RESPIMAT locking mechanism will be engaged and no more actuations can be dispensed.
After assembly, the SPIRIVA RESPIMAT inhaler should be discarded at the latest 3 months after first use or when the locking mechanism is engaged, whichever comes first.
Keep out of reach of children. Do not spray into eyes.
Storage
Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Avoid freezing.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7b656b14-fcaa-2741-f6f0-e0be48971c02


SPIRIVA®RESPIMAT®(噻托溴铵)喷雾吸入现在可以在美国的哮喘维持治疗成人和青少年
SPIRIVA RESPIMAT在第一类新的吸入药物的核可在10年以上的为治疗哮喘
SPIRIVA RESPIMAT作品不同于其他药物,以帮助哮喘病人呼吸更顺畅
2016年2月3日,美国食品和药物管理局FDA批准SPIRIVA RESPIMAT 2.5微克的人12岁及以上的长期维持治疗哮喘(在2喷1.25微克每递送)的每日一次的剂量。 SPIRIVA RESPIMAT不是突然哮喘症状的治疗。在治疗哮喘,肺功能最大的收益最多可能需要4〜8周给药。
“尽管服用其他日常维护治疗,很多哮喘病人继续体验症状,包括咳嗽,喘息,呼吸急促,说:”迈克尔B. Foggs,MD,过敏和免疫学主任,倡导医疗集团,倡导医疗保健芝加哥, IL。 “对于这些患者,增加SPIRIVA RESPIMAT维护控制器疗法可能有助于打开气道,以改善呼吸和减少哮喘的突发或加重的可能性*。”
一项调查发现的哮喘病人服用至少一种处理还是经验丰富的症状,它可以对他们进行日常活动的能力产生负面影响55%。
不像其他哮喘每日维持治疗,SPIRIVA RESPIMAT是从一个新的类被称为长效毒蕈碱拮抗剂(喇嘛)在哮喘药物的,第一个新的类吸入药物的超过10年哮喘批准英寸作为一个喇嘛,它是类固醇免费,工作方式与一个长效β2-受体激动剂(LABA)。
SPIRIVA RESPIMAT在两个不同的剂量,一个用于哮喘和一个用于COPD的批准。对于哮喘,它被批准作为每日一次的剂量2.5微克(在2喷1.25微克每递送)的。 SPIRIVA RESPIMAT也被批准为每日一次剂量为5微克的维持治疗慢性阻塞性肺病(在2喷2.5微克每递送)。这两种剂量SPIRIVA RESPIMAT应每天服用一次为2喷。
“随着呼吸的行业领导者,勃林格殷格翰公司致力于解决未满足的需求,并改善病人护理对那些有严重呼吸系统疾病,如哮喘,”克莱尔挖洞,副总裁,市场营销呼吸,勃林格殷格翰制药公司说“ SPIRIVA RESPIMAT的批准标志着我们进入哮喘空间,我们很自豪能够提供医疗保健提供者和患者的新方法,以考虑哮喘的治疗。“
FDA批准SPIRIVA RESPIMAT哮喘基于疗效和安全性的数据从一个全面的临床试验方案治疗,其中包括约5000名成年人12项试验和青少年轻度,中度和重度症状的哮喘在至少一种吸入性皮质激素(ICS)或ICS / LABA。
关于RESPIMAT吸入器
该RESPIMAT对于勃林格殷格翰呼吸治疗平台吸入器。 RESPIMAT是主动提供了一个缓慢移动的薄雾,帮助患者吸入药物的唯一吸入器。
该RESPIMAT吸入用药提供独立吸气努力的程度或强度。如同所有的吸入药物,输送到肺部药物的实际量可以取决于患者因素,如通过递送系统的吸入器的致动和灵感之间的协调。吸入的持续时间应该至少只要喷雾持续时间(1.5秒)。
关于COPD SPIRIVA RESPIMAT
此FDA批准用于治疗哮喘为SPIRIVA RESPIMAT,其已经被批准用于长期,每日一次维护支气管痉挛的与COPD相关的治疗,包括慢性支气管炎和肺气肿,并减少在COPD患者病情加重的第二指示。 SPIRIVA RESPIMAT是不是急性支气管痉挛救济表示。
适应症
SPIRIVA RESPIMAT,2.5微克/驱动,是一个长期的,每日一次,处方保养用来控制放松你的气道并保持通畅慢性阻塞性肺疾病(COPD)症状的药物。慢性阻塞性肺病包括慢性支气管炎和肺气肿。 SPIRIVA RESPIMAT也减少COPD的突发(COPD急性加重)的可能性。
SPIRIVA RESPIMAT,1.25微克/致动,是一个长期的,每日一次,处方维持治疗哮喘的人12岁以上。
SPIRIVA RESPIMAT不是哮喘或慢性阻塞性肺病的突然症状的治疗。
重要安全信息
不要使用SPIRIVA RESPIMAT如果你是噻托溴铵,异丙托溴铵​​,阿托品或同类药物,或这些药物的任何成分过敏。
SPIRIVA RESPIMAT不是抢救药物,不应该被用于治疗突然呼吸问题。你的医生可能会给你其他的药用于突发呼吸问题。
SPIRIVA RESPIMAT可引起过敏反应。症状包括你的皮肤上(荨麻疹),瘙痒,皮疹和/或嘴唇,舌头或咽喉可能导致呼吸或吞咽困难肿胀凸起的红色斑块。如果你有这些症状,停止服用药物,并寻求紧急医疗照顾。
SPIRIVA RESPIMAT可能会导致你的呼吸突然变得更糟(支气管痉挛)。如果发生这种情况,用你的救援吸入器,停止服用SPIRIVA RESPIMAT,并打电话给医生立即或寻求紧急医疗护理。
SPIRIVA RESPIMAT可以增加你的眼睛压力(急性闭角型青光眼),这可能会导致以下症状:眼痛,视力模糊,看晕轮或彩色图像,红色的眼睛一起。如果你有这些症状,停止服用药物,并打电话给你的医生。
头晕眼花可以用SPIRIVA RESPIMAT发生。如果出现这些症状,在活动,如驾驶汽车,或经营家电或其他机器参与时要谨慎。
SPIRIVA RESPIMAT可以引起新的或恶化的尿潴留。在你的膀胱和/或前列腺肥大堵塞的症状包括排尿困难和/或排尿疼痛。如果你有这些症状,停止服用药物,并打电话给你的医生。
最常见的副作用COPD患者SPIRIVA RESPIMAT报道包括咽痛,咳嗽,口干,和鼻窦感染。
最常见的副作用与成人哮喘患者SPIRIVA RESPIMAT是喉咙痛,鼻窦感染,支气管炎,头痛。
别喷SPIRIVA RESPIMAT你的眼睛,因为这可能造成视力和散瞳模糊。
告诉你的医生你的所有的医疗条件,包括肾脏疾病,青光眼,前列腺肥大,小便,或堵塞你的膀胱问题。
告诉您的医生您服用的所有药物,包括眼药水。问问你的医生,如果你正在服用抗胆碱任何药物,因为服用它们连同SPIRIVA RESPIMAT可以增加副作用。

责任编辑:admin


相关文章
ENCRUSE 62.5μg ELLIPTA(Umeclidinium Bromide)
Myocor spray(硝酸甘油舌下喷雾)
Spiriva Respimat(Tiotropium Bromide Hydrate)噻托溴安粉吸入剂
Meptin inhalation solution(盐酸丙卡特罗吸入溶液)
妥布霉素吸入干粉|TOBI Podhaler(Tobramycin Inhalation Powder)
DESMOPRESSIN Spray(醋酸去氨加压素喷雾剂)
FIBLAST Spray(曲弗明重组喷雾剂)
STIOLTO RESPIMAT(tiotropium bromide and olodaterol)
Seebri Breezhaler(格隆溴铵吸入性胶囊)
Duaklir Genuair(复方阿地溴铵/富马酸福莫特罗吸入干粉剂)
 

最新文章

更多

· SPIRIVA RESPIMAT(tiotr...
· Odefsey(rilpivirine/em...
· 依鲁替尼硬胶囊|IMBRUVI...
· Briviact(Brivaracetam...
· Nucala(mepolizumab po...
· 阿西替尼片|INLYTA(axit...
· DAKLINZA(daclatasvir t...
· Sylvant(siltuximab)注...
· Alecensa(Alectinib Cap...
· Empliciti(elotuzumab)埃...

推荐文章

更多

· SPIRIVA RESPIMAT(tiotr...
· Odefsey(rilpivirine/em...
· 依鲁替尼硬胶囊|IMBRUVI...
· Briviact(Brivaracetam...
· Nucala(mepolizumab po...
· 阿西替尼片|INLYTA(axit...
· DAKLINZA(daclatasvir t...
· Sylvant(siltuximab)注...
· Alecensa(Alectinib Cap...
· Empliciti(elotuzumab)埃...

热点文章

更多

· Briviact(Brivaracetam...
· Odefsey(rilpivirine/em...
· 依鲁替尼硬胶囊|IMBRUVI...
· SPIRIVA RESPIMAT(tiotr...